(Q50862636)

24 March 2018

title

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies? (English)

1 reference

24 March 2018

author

Jens Juul Holst

series ordinal

1

1 reference

24 March 2018

publication date

3 July 2013

1 reference

24 March 2018

published in

Diabetologia

1 reference

24 March 2018

volume

56

1 reference

24 March 2018

issue

9

1 reference

24 March 2018

page(s)

1869-1872

1 reference

24 March 2018

https://scigraph.springernature.com/pub.10.1007/s00125-013-2984-z

exact match

0 references

cites work

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Incretin therapy and islet pathology: a time for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Drug-grapefruit juice interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2984-Z

Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells

21 January 2018

1 reference

12 December 2020

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini

1 reference

12 December 2020

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

1 reference

12 December 2020

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.

1 reference

12 December 2020

Role of glucagon in maintenance of euglycemia in fed and fasted rats.

1 reference

12 December 2020

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

1 reference

12 December 2020

Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas

1 reference

12 December 2020

Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat -Cells by a Protein Kinase A-Mediated Mechanism

1 reference

12 December 2020

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

12 December 2020

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

12 December 2020

10.1007/S00125-013-2984-Z

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018